Business Wire

Rigaku and SPERA PHARMA Initiate Strategic Partnership to Advanced Pharmaceutical Development

Share

Rigaku Corporation, a Group company of Rigaku Holdings Corporation (headquarters: Akishima, Tokyo; CEO: Jun Kawakami; hereinafter “Rigaku”), and SPERA PHARMA, Inc. (headquarters: Osaka; President & Representative Director: Keitaro Iwaki; hereinafter “SPERA PHARMA”) have initiated a strategic partnership aimed at accelerating and transforming pharmaceutical development by leveraging the two companies’ cutting-edge technologies and extensive expertise.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250417047994/en/

Left: Keitaro Iwaki, President & Representative Director, SPERA PHARMA; Right: Jun Kawakami, President & CEO, Rigaku

SPERA PHARMA will use XtaLAB Synergy-ED, an integrated platform for electronic diffraction provided by Rigaku, for contract analytical services, thereby offering customers robust support in pharmaceutical development.

The XtaLAB Synergy-ED incorporates 3D ED/MicroED1, which is utilized for the structure analysis of substances, including microscopic crystals and minute quantities of crystalline powder. This sophisticated technology provides sufficiently high resolution to determine atomic-level structures, enabling the detailed elucidation of molecular structures of organic compounds and similar substances.

SPERA PHARMA is currently the world’s only company in the pharmaceutical industry offering contract analytical services with the XtaLAB Synergy-ED. Rigaku will extend technical support to SPERA PHARMA for its contract analytical operations.

Furthermore, the two companies are collaborating closely to advance research utilizing the XtaLAB Synergy-ED and to actively share information on the application methods and analytical technologies.

Through this partnership, Rigaku and SPERA PHARMA aim to provide robust support at the forefront of pharmaceutical development, playing pivotal roles in pioneering the future of medicine.

1: Stands for “Three-Dimensional Electron Diffraction/Microcrystal Electron Diffraction.” A method for analysis of crystalline structures using electronic diffraction.

Example of Joint Research and Use
“Detection of Hydrogen Atoms Using Only 3D ED/MicroED and Contribution to Structure Determining Salts or Cocrystals,” Crystal Growth Design, 2025, 25, 1, 129–135
URL: https://pubs.acs.org/doi/10.1021/acs.cgd.4c01421
(Registration required to read.)

About the Rigaku Group

Since its establishment in 1951, the engineering professionals of the Rigaku group have been dedicated to benefiting society with leading-edge technologies, notably including its core fields of X-ray and thermal analysis. With a market presence in over 90 countries and some 2,000 employees from 9 global operations, Rigaku is a solution partner in industry and research analysis institutes. Our overseas sales ratio has reached approximately 70% while sustaining an exceptionally high market share in Japan. Together with our customers, we continue to develop and grow. As applications expand from semiconductors, electronic materials, batteries, environment, resources, energy, life science to other high-tech fields, Rigaku realizes innovations “To Improve Our World by Powering New Perspectives.”
For details, please visit rigaku-holdings.com/english

About SPERA PHARMA

SPERA PHARMA was established in July 2017 in the Juso area of Yodogawa-ku, Osaka. It is a contract development and manufacturing organization (CDMO) specializing in Chemistry, Manufacturing and Controls (CMC) pharmaceutical sciences, including process chemistry, formulation development, and analytical development, as well as the manufacturing of investigational drugs. The company’s expert research team, which has extensive experience and proven results, works flexibly in all phases of pharmaceutical development from the early stage to final drug application. SPERA PHARMA is a one-stop provider of comprehensive services and solutions to meet customer needs. For further information, please visit spera-pharma.co.jp/en

View source version on businesswire.com: https://www.businesswire.com/news/home/20250417047994/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Tahoe Therapeutics Selects Parse Biosciences’ GigaLab to Generate 300 Million Single Cell Profiles for Large-Scale Perturbation Atlas11.12.2025 14:00:00 CET | Press release

Parse’s GigaLab to provide industry leading, large-scale, single cell services to support Tahoe’s development of foundational biological datasets Parse Biosciences, a leading provider of accessible and scalable single cell sequencing solutions, today announced that Tahoe Therapeutics has selected Parse’s GigaLab to generate data for its upcoming 300M cell project. Tahoe will use its proprietary Mosaic technology to generate samples consisting of 300M cells from large arrays of disease models, genetically or chemically perturbed. Under this agreement, Parse will apply its Evercode™ chemistry and high-throughput automation to these samples to deliver the largest perturbation-focused single cell dataset ever produced. Parse’s GigaLab, designed specifically for million- to hundred-million-cell projects, has rapidly become an industry benchmark for large-scale, reproducible single cell data generation. The facility integrates high-capacity liquid handling, standardized workflows, and end-to

Xsight Labs X2 Switch to Enable Next-Generation Starlink Satellites and Deliver Gigabit Connectivity11.12.2025 14:00:00 CET | Press release

High-bandwidth, ultra-low-power chip is leveraged for Starlink V3 satellites and future next-generation communication systems. News Highlights: Xsight’s X2 switch enables Starlink V3 satellite Delivers the performance required for rapid data processing, stable telemetry, and real-time operational responsiveness for Starlink X2’s flexible, programmable architecture adapts seamlessly to diverse orbital and ground-based networking workloads Xsight Labs, an innovator in high-performance connectivity silicon, today announced that Starlink, the world’s most advanced satellite constellation in low-Earth orbit, delivering broadband, will leverage the Xsight X2 Programmable Ethernet switch to serve as the high-speed networking core for its next-generation Starlink V3 satellites. Each V3 Starlink satellite is designed to deliver more than 1 terabit per second (Tbps) of fronthaul throughput, more than 10× the capacity delivered by Starlink V2 Mini satellites, and about 160 gigabits per second (Gb

Payments Leaders Unprepared for 2026 Disruption, Warns ACI Worldwide11.12.2025 13:00:00 CET | Press release

ACI’s Top Ten Payments Predictions for 2026 urges payments leaders to act amid structural shifts in global payments Most global payments leaders lack a clear roadmap to navigate the seismic changes coming in 2026 , according to the latest Top Ten Payments Predictions from ACI Worldwide (NASDAQ: ACIW), an original innovator in global payments technology. With AI-driven intelligence, next-gen authentication, new regulatory frameworks, and soaring demand for instant, embedded, and secure payments, the industry is entering an era of structural disruption. However, ACI’s recent report Payments in Transition: Leadership in an era of transformation reveals that only 36% of payments executives have a clear long-term modernization roadmap, leaving many without a strategic vision for transformation. “In 2026, payments disruption won’t be incremental—it will be structural,” said Philip Bruno, Chief Strategy and Growth Officer at ACI Worldwide. “Real-time is now the baseline, digital assets are en

Andersen Global styrker sine vurderingskapaciteter i Asien og Stillehavsområdet med ETC11.12.2025 12:29:00 CET | Pressemeddelelse

Andersen Global fortsætter med at udvide sin tilstedeværelse i Asien og Stillehavsområdet gennem en samarbejdsaftale med Edmund Tie & Company (ETC), et full-service ejendomsrådgivningsfirma med hovedsæde i Singapore. ETC blev stiftet i 1995 og leverer vurderings- og rådgivningsydelser på tværs af ejendommens livscyklus, herunder lovpligtig og selskabsrelateret vurdering, investeringsrådgivning, feasibility-analyser og rådgivning om ejendomsskat. Med aktiviteter i Singapore, Malaysia og Thailand kombinerer ETC dybdegående regional viden med internationale standarder for at støtte udviklere, investorer, private og statslige fonde, selskaber, REIT'er samt ejere og lejere. Firmaet er kendt for sin forskningsbaserede tilgang og integrerede servicemodel og hjælper kunder med at navigere i komplekse lovgivninger og optimere værdien af deres aktiver. "Vores styrke ligger ikke kun i den tekniske udførelse, men i at hjælpe kunder med at se det fulde billede – at forbinde markedssignaler, lovgivn

AB InBev and International Cricket Council Announce Landmark Global Partnership11.12.2025 10:31:00 CET | Press release

World’s Leading Brewer becomes the Official Beer Partner of the ICC The International Cricket Council (ICC) announced AB InBev (Euronext: ABI) (NYSE: BUD) (MEXBOL: ANB) (JSE: ANH), the world’s leading brewer, will become the Official Beer Partner for all major ICC tournaments starting in 2026. The partnership will be led by Budweiser 0.0, Budweiser’s no-alcohol beer in India, with other ABI mega brands activating in Europe and Africa. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251211250826/en/ AB InBev and ICC announce global partnership From attending a match live in-stadium to watching one at a bar or pub with friends, with a lower alcohol-by-volume (ABV) and no-alcohol options like Budweiser 0.0, beer is the natural choice to enjoy responsibly. Through this partnership with the ICC, AB InBev will create more moments of cheers, choice and celebration for cricket fans of legal drinking age all over the world. ICC CEO, S

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye